title: Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis.
abstract: The aim of the study was to characterise the profile and clinical correlates (arthritis, rash, and fatigue) of cytokines, chemokines, and other mediators in symptomatic acute parvovirus B19 infection. Serum was examined from cases of acute B19 infection (as defined by serum anti-B19 IgM positivity) (n = 84), and in normal persons (n = 43) for B19 markers (serum B19 antibodies and DNA), rheumatoid factor (RF), and antinuclear antibody (ANA). A panel of cytokines/chemokines was measured in duplicate using the Bioplex Protein Array system (BioRad Hemel Hempstead, UK). These included interleukin-1 beta (IL-1 beta), IL-4, IL-5, IL-6, IL-8, IL-13, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), macrophage chemoattractant protein-1 (MCP-1), granulocyte-monocyte colony stimulating factor (GM-CSF), transforming growth factor-beta1 (TGF-beta 1), endothelin-1 (ET-1), and neopterin. Acute symptomatic infection was characterised by specific IgG positivity (83%), serum B19 DNA positivity (96%), and raised levels of IL-4, IL-6, IL-8, TNF-alpha, IFN-gamma, MCP-1, GM-CSF, TGF-beta 1, and ET-1. Patients with acute B19-associated arthritis were found to have lower levels of IL-6, TNF-alpha, and GM-CSF than patients without arthritis, while those with rash had lower levels of TGF-beta 1. It is concluded that cytokine levels following acute symptomatic infection with parvovirus B19 indicate a state of immune activation. The profile of circulating mediators may provide insights into the possible pathogenesis of particular clinical manifestations of this infection.
authors.affiliation: Department of Microbiology, Royal Brompton Hospital, National Heart & Lung Institute, Imperial College London, London, United Kingdom. j.kerr@imperial.ac.uk
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Kerr
authors.forename: Victoria S
authors.initials: VS
authors.lastname: Cunniffe
authors.forename: Peter
authors.initials: P
authors.lastname: Kelleher
authors.forename: Andrew J S
authors.initials: AJ
authors.lastname: Coats
authors.forename: Derek L
authors.initials: DL
authors.lastname: Mattey
mesh_terms: D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001170:Arthritis, Infectious / Q000821:virology; D016022:Case-Control Studies; D018925:Chemokines / Q000097:blood*; D002648:Child; D016207:Cytokines / Q000097:blood*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000276:immunology* / Q000821:virology*; D016732:Parvovirus B19, Human / Q000276:immunology*; D011237:Predictive Value of Tests; D012217:Rheumatoid Factor / Q000097:blood; D012307:Risk Factors
chemical_list: D000974:Antibodies, Antinuclear; D000914:Antibodies, Viral; D018925:Chemokines; D016207:Cytokines; D004279:DNA, Viral; D007074:Immunoglobulin G; D012217:Rheumatoid Factor